User profiles for Josée M. Zijlstra
 | Josée ZijlstraAssociate Professor of Hematology, VU University Medical Center, Amsterdam Verified email at vumc.nl Cited by 16109 |
[HTML][HTML] Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma
…, JP De Boer, JM Zijlstra… - … England Journal of …, 2015 - Mass Medical Soc
Background Survivors of Hodgkin’s lymphoma are at increased risk for treatment-related
subsequent malignant neoplasms. The effect of less toxic treatments, introduced in the late …
subsequent malignant neoplasms. The effect of less toxic treatments, introduced in the late …
[PDF][PDF] Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes
…, EM Noordijk, MW Louwman, JM Zijlstra… - J Clin Oncol, 2009 - academia.edu
… van’t Veer, Evert M. Noordijk, Marieke WJ Louwman, Josée M. Zijlstra, Hendrik van den
Berg, Nicola S. Russell, Margreet HA Baaijens Collection and assembly of data: Marie L. De …
Berg, Nicola S. Russell, Margreet HA Baaijens Collection and assembly of data: Marie L. De …
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
…, O Casasnovas, N Hamad, JM Zijlstra… - The Lancet …, 2020 - thelancet.com
Background Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive
cancer with a median overall survival of less than 6 months. We aimed to assess the …
cancer with a median overall survival of less than 6 months. We aimed to assess the …
[PDF][PDF] Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial
…, R Greil, MS Topp, J Meissner, JM Zijlstra, M Soekler… - J Clin …, 2012 - medspec.co.za
Purpose In patients with early unfavorable Hodgkin’s lymphoma (HL), combined modality
treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and …
treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and …
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the …
…, JM Zijlstra, J Markova, J Meissner, M Feuring-Buske… - The Lancet, 2017 - thelancet.com
… Josée M Zijlstra, MD Josée M Zijlstra … eBEACOPP was given as previously described;
rituximab was given intravenously at a dose of 375 mg/m 2 (maximum total dose 700 mg). The …
rituximab was given intravenously at a dose of 375 mg/m 2 (maximum total dose 700 mg). The …
A guide to ComBat harmonization of imaging biomarkers in multicenter studies
…, JM Zijlstra, C Thieblemont, M Meignan… - Journal of Nuclear …, 2022 - Soc Nuclear Med
The impact of PET image acquisition and reconstruction parameters on SUV measurements
or radiomic feature values is widely documented. This scanner effect is detrimental to the …
or radiomic feature values is widely documented. This scanner effect is detrimental to the …
18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review
JM Zijlstra, G Lindauer-van der Werf… - …, 2006 - haematologica.org
Despite the increasing number of publications concerning 18F-fluorodeoxyglucose positron
emission tomography (FDG-PET) for post-treatment evaluation of lymphoma and the …
emission tomography (FDG-PET) for post-treatment evaluation of lymphoma and the …
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label …
…, JM Zijlstra, R Greil, J Markova, S Sasse, M Fuchs… - The Lancet, 2015 - thelancet.com
Background The role of bleomycin and dacarbazine in the ABVD regimen (ie, doxorubicin,
bleomycin, vinblastine, and dacarbazine) has been questioned, especially for treatment of …
bleomycin, vinblastine, and dacarbazine) has been questioned, especially for treatment of …
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
…, A Hüttmann, M Wilhelm, JM Zijlstra… - The Lancet …, 2021 - thelancet.com
Background Combined-modality treatment consisting of chemotherapy and consolidation
radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin lymphoma. …
radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin lymphoma. …
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial
…, MB van't Veer, JM Zijlstra… - Blood, The Journal …, 2008 - ashpublications.org
We evaluated the role of rituximab during remission induction chemotherapy in relapsed
aggressive CD20 + non-Hodgkin lymphoma. Of 239 patients, 225 were evaluable for analysis. …
aggressive CD20 + non-Hodgkin lymphoma. Of 239 patients, 225 were evaluable for analysis. …